Stoke Therapeutics to Present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
– New preclinical data support the ongoing preclinical development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA) –
– ADOA is the most common inherited optic nerve disorder –
The presentation details are as follows:
Title: STK-002, an Antisense Oligonucleotide (ASO) for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), is Taken Up by
Presenter:
Session: Gene therapy and other novel therapeutics in ophthalmic diseases 1
Date and Time:
Presentation Number: 1111
Title: Models of Autosomal Dominant Optic Atrophy (ADOA) using OPA1 haploinsufficient iPSCs and response to Targeted Augmentation of Nuclear Gene Output (TANGO) Antisense Oligonucleotides (ASOs) Treatment
Presenter:
Session: Animal models of human ocular disease
Date and Time:
Poster Number: 1895 – A0041
About TANGO
TANGO (Targeted Augmentation of Nuclear Gene Output) is Stoke’s proprietary research platform. Stoke’s initial application for this technology are diseases in which one copy of a gene functions normally and the other is mutated, also called haploinsufficiencies. In these cases, the mutated gene does not produce its share of protein, so the body does not function normally. Using the TANGO approach and a deep understanding of RNA science, Stoke researchers design antisense oligonucleotides (ASOs) that bind to pre-mRNA and help the target genes produce more protein. TANGO aims to restore missing proteins by increasing – or stoking – protein output from healthy genes, thus compensating for the non-functioning copy of the gene.
About Autosomal Dominant Optic Atrophy (ADOA)
Autosomal dominant optic atrophy is the most common inherited optic nerve disorder. It is a rare disease that causes progressive and irreversible vision loss in both eyes starting in the first decade of life. Severity can vary and the rate of vision loss can be difficult to predict. Roughly half of people with ADOA fail driving standards and up to 46% are registered as legally blind. ADOA is considered a haploinsufficiency disease, as most people living with ADOA have genetic mutations in the OPA1 gene that result in only half the necessary OPA1 protein being produced. More than 400 OPA1 mutations have been reported in people diagnosed with ADOA. Currently there is no approved treatment for people living with ADOA. ADOA affects approximately one in 30,000 people globally with a higher incidence in
About STK-002
STK-002 is a proprietary antisense oligonucleotide (ASO) in preclinical development for the treatment of Autosomal Dominant Optic Atrophy (ADOA). Stoke believes that STK-002 has the potential to be the first disease-modifying therapy for people living with ADOA. STK-002 is designed to upregulate OPA1 protein expression by leveraging the non-mutant (wild-type) copy of the OPA1 gene to restore OPA1 protein expression with the aim to stop or reverse vision loss in patients with ADOA. Stoke has generated preclinical data demonstrating proof-of-mechanism and proof-of-concept for STK-002.
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005105/en/
Stoke Media & Investor Contacts:
Chief Communications Officer
dkalmar@stoketherapeutics.com
781-303-8302
Vice President, Investor Relations
IR@stoketherapeutics.com
617-312-2754
Source: